1. Home
  2. LRE vs ELTX Comparison

LRE vs ELTX Comparison

Compare LRE & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LRE
  • ELTX
  • Stock Information
  • Founded
  • LRE 2001
  • ELTX 2011
  • Country
  • LRE Japan
  • ELTX United States
  • Employees
  • LRE N/A
  • ELTX N/A
  • Industry
  • LRE
  • ELTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • LRE
  • ELTX Health Care
  • Exchange
  • LRE Nasdaq
  • ELTX Nasdaq
  • Market Cap
  • LRE 24.4M
  • ELTX 121.7M
  • IPO Year
  • LRE 2023
  • ELTX N/A
  • Fundamental
  • Price
  • LRE $1.80
  • ELTX $9.20
  • Analyst Decision
  • LRE
  • ELTX Strong Buy
  • Analyst Count
  • LRE 0
  • ELTX 2
  • Target Price
  • LRE N/A
  • ELTX $9.50
  • AVG Volume (30 Days)
  • LRE 9.3K
  • ELTX 47.4K
  • Earning Date
  • LRE 01-01-0001
  • ELTX 08-12-2025
  • Dividend Yield
  • LRE N/A
  • ELTX N/A
  • EPS Growth
  • LRE N/A
  • ELTX N/A
  • EPS
  • LRE N/A
  • ELTX N/A
  • Revenue
  • LRE $110,330,328.00
  • ELTX N/A
  • Revenue This Year
  • LRE N/A
  • ELTX N/A
  • Revenue Next Year
  • LRE N/A
  • ELTX N/A
  • P/E Ratio
  • LRE N/A
  • ELTX N/A
  • Revenue Growth
  • LRE 3.92
  • ELTX N/A
  • 52 Week Low
  • LRE $1.10
  • ELTX $3.70
  • 52 Week High
  • LRE $2.49
  • ELTX $9.99
  • Technical
  • Relative Strength Index (RSI)
  • LRE 57.95
  • ELTX 68.72
  • Support Level
  • LRE $1.72
  • ELTX $7.97
  • Resistance Level
  • LRE $1.78
  • ELTX $8.94
  • Average True Range (ATR)
  • LRE 0.08
  • ELTX 0.41
  • MACD
  • LRE -0.01
  • ELTX 0.03
  • Stochastic Oscillator
  • LRE 36.73
  • ELTX 96.74

About LRE Lead Real Estate Co. Ltd

Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.

Share on Social Networks: